Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ArriVent BioPharma, Inc. (AVBP)

ArriVent Doses First U.S. Patient in Phase 1 Trial of ARR-002 ADC for Gynecologic Cancers

Neutral Impact 2 of 5 other Written later

ArriVent BioPharma announced on October 12, 2026 that it dosed the first U.S. patient in a Phase 1 trial of ARR-002, a MUC16/NaPi2b dual-target antibody-drug conjugate for ovarian and endometrial cancer. The filing reports no financial results, guidance, or cost figures, so the update is a clinical development milestone for the company's pipeline.

Key points

  • First U.S. patient dosed in the Phase 1 trial of ARR-002 (NCT07755436), announced October 12, 2026
  • ARR-002 is described as the company's second ADC to enter the clinic
  • In August 2026, ArriVent licensed ARR-002 to Shanghai Allist Pharmaceuticals for Greater China, with other rights retained by ArriVent

The filing

CompanyArriVent BioPharma, Inc. (AVBP)
Form8-K, current report
Filed with the SECOct 13, 2026, 6:03 AM ET
Accession number0001104659-26-115161

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.